Europska Unija - hrvatski - EMA (European Medicines Agency)

sandoz gmbh - epoetin alfa - anemia; kidney failure, chronic - antianemijski pripravci - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients: , treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis;, treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis;, treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e. stanje kardiovaskularnog sustava, već postojeće anemije u početku kemoterapije).

Europska Unija - hrvatski - EMA (European Medicines Agency)

recordati rare diseases - merkaptamin bitartrat - cystinosis - drugi gastrointestinalni trakt i metabolizam, lijekovi, - cystagon je indiciran za liječenje dokazane nefropatske cistinoze. cisteamin smanjuje nakupljanje cisteina u nekim stanicama (npr. leukocita, mišića i jetrenih stanica) pacijenata s nefropatskim cistinozom i, kada se liječenje započne rano, odgađa razvoj zatajenja bubrega.

Europska Unija - hrvatski - EMA (European Medicines Agency)

hexal ag - epoetin alfa - anemia; kidney failure, chronic; cancer - antianemijski pripravci - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients: , treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis;, treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. liječenje anemije i smanjenje potrebe transfuzije krvi kod odraslih pacijenata koji primaju kemoterapiju za uglednih tumora maligni limfom ili multiple myeloma, kao i na rizik трансфузии оцениваемым opće stanje pacijenta (e. stanje kardiovaskularnog sustava, već postojeće anemije u početku kemoterapije).

Europska Unija - hrvatski - EMA (European Medicines Agency)

pfizer limited - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastična sredstva - gastrointestinal stromal tumour (gist)sutent is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib mesilate treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sutent is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sutent is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults. experience with sutent as first-line treatment is limited (see section 5.

Europska Unija - hrvatski - EMA (European Medicines Agency)

noden pharma dac - Алискирен, hidroklorotiazid - hipertenzija - sredstva koja djeluju na sustav renin-angiotenzina - liječenje esencijalne hipertenzije kod odraslih osoba. rasilez hct je drugačije kod pacijenata kod kojih je krvni pritisak nije dovoljno prati na алискирена i hidroklorotiazid se koristi samo. rasilez hct je naveden kao zamjenska terapija kod bolesnika adekvatno upravlja pomoću алискирена i hidroklorotiazid, istovremeno, na istoj razini doze u kombinaciji.

Europska Unija - hrvatski - EMA (European Medicines Agency)

novartis europharm limited  - onasemnogene abeparvovec - mišićna atrofija, kralješnica - ostali lijekovi za poremećaje mišićno-koštanog sustava - zolgensma indiciran za liječenje bolesnika s 5v spinalne mišićne atrofije (agr) sa bi-аллельные mutacije u genu smn1 i kliničku dijagnozu agr tip 1, orpatients sa 5v agr s bi-аллельные mutacije u genu smn1 i do 3-x kopija gena smn2.

Europska Unija - hrvatski - EMA (European Medicines Agency)

accord healthcare s.l.u. - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastična sredstva - gastrointestinal stromal tumour (gist)sunitinib accord is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sunitinib accord is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sunitinib accord is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (pnet) with disease progression in adults.

Europska Unija - hrvatski - EMA (European Medicines Agency)

pfizer europe ma eeig  - axitinib - karcinom, stanice bubrega - inhibitori протеинкиназы - inlyta is indicated for the treatment of adult patients with advanced renal cell carcinoma (rcc) after failure of prior treatment with sunitinib or a cytokine.

Europska Unija - hrvatski - EMA (European Medicines Agency)

vifor fresenius medical care renal pharma france - kalcijevu otopinu - hiperkalijemija - lijekovi za liječenje hiperkalemiju i гиперфосфатемии - veltassa je indicirana za liječenje hiperkalemije kod odraslih osoba.

Europska Unija - hrvatski - EMA (European Medicines Agency)

sanofi b.v. - sevelamer karbonat - hyperphosphatemia; renal dialysis - svi ostali terapeutski proizvodi - renvela je indicirana za kontrolu hiperfosfatemije kod odraslih osoba koje primaju hemodijalizu ili peritonealnu dijalizu. renvela također je prikazano za kontrolu hyperphosphataemia u odraslih bolesnika s kroničnom bolešću bubrega bez dijalizu s fosfora u serumu ≥ 1. 78 mmol/l. renvela treba koristiti u okviru nekoliko terapijskih pristupa koji se mogu uključiti dodataka kalcija, 1,25-дигидрокси vitamin d3 ili jedan od njegovih analoga za praćenje razvoja bolesti bubrega канальцах .